Phase III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

Trial Profile

Phase III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 May 2017

At a glance

  • Drugs Vosaroxin (Primary) ; Cytarabine; Daunorubicin; Idarubicin; Methotrexate; Mycophenolic acid
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms BIG-1
  • Most Recent Events

    • 20 May 2017 New trial record
    • 08 May 2017 According to Sunesis Pharmaceuticals media release, vosaroxin has been selected as a treatment arm in this trial, which is expected to begin dosing imminently and will enroll up to 200 patients with favorable or intermediate risk AML, who will receive consolidation therapy of intermediate dose cytarabine with vosaroxin.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top